The Potential to Combine KIT and CTLA-4 Blockade in Patients With GIST
William D. Tap, MD, discusses the potential to combine KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.
Clinical Pearls
William D. Tap, MD, Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential to combine KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.
- When GIST respond to imatinib, an important immune-mediated response occurs. Research has shown that an immune response is often responsible for the development of resistance to drugs such as imatinib.
- If a checkpoint inhibitor is given after a TKI, an improvement in the immune response is seen.
- As drug resistance makes GIST difficult to treat, the hope is that combining drugs such as dastinib and ipilimumab may be a new option for patients.
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
